CD47 and neoplasm: The closure of CD47 ECD antibody programs by large pharmaceutical companies (see NCT05626322 and others) could be anticipated given contradictory data showing that while the loss of CD47 ECD led to SIRPα activation, this was insufficient to account for the increased tumor clearance observed in rodent studies [180,181], and assumes more value in the models used over the evolutionarily conserved functions of the CD47 ECD with protein sequence homology across species [39,182,183].